Literature DB >> 33960559

Transplantation of tauroursodeoxycholic acid-inducing M2-phenotype macrophages promotes an anti-neuroinflammatory effect and functional recovery after spinal cord injury in rats.

Gong Ho Han1,2, Seong Jun Kim1,2, Wan-Kyu Ko1,2, Daye Lee1,2, In-Bo Han1, Seung Hun Sheen1, Je Beom Hong3, Seil Sohn1.   

Abstract

OBJECTIVES: In this study, we study the transplantation of tauroursodeoxycholic acid (TUDCA)-induced M2-phenotype (M2) macrophages and their ability to promote anti-neuroinflammatory effects and functional recovery in a spinal cord injury (SCI) model.
METHODS: To this end, compared to the granulocyte-macrophage colony-stimulating factor (GM-CSF), we evaluated whether TUDCA effectively differentiates bone marrow-derived macrophages (BMDMs) into M2 macrophages.
RESULTS: The M2 expression markers in the TUDCA-treated BMDM group were increased more than those in the GM-CSF-treated BMDM group. After the SCI and transplantation steps, pro-inflammatory cytokine levels and the mitogen-activated protein kinase (MAPK) pathway were significantly decreased in the TUDCA-induced M2 group more than they were in the GM-CSF-induced M1 group and in the TUDCA group. Moreover, the TUDCA-induced M2 group showed significantly enhanced tissue volumes and improved motor functions compared to the GM-CSF-induced M1 group and the TUDCA group. In addition, biotinylated dextran amine (BDA)-labelled corticospinal tract (CST) axons and neuronal nuclei marker (NeuN) levels were increased in the TUDCA-induced M2 group more than those in the GM-CSF-induced M1 group and the TUDCA group.
CONCLUSIONS: This study demonstrates that the transplantation of TUDCA-induced M2 macrophages promotes an anti-neuroinflammatory effect and motor function recovery in SCI. Therefore, we suggest that the transplantation of TUDCA-induced M2 macrophages represents a possible alternative cell therapy for SCI.
© 2021 The Authors. Cell Proliferation Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bone marrow-derived macrophages; neuroinflammation; spinal cord injuries; tauroursodeoxycholic acid; transplantation

Year:  2021        PMID: 33960559     DOI: 10.1111/cpr.13050

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  6 in total

1.  Neuron-inducing therapy using embryonic neural progenitor cells embedding positively charged gold nanoparticles in rats with complete spinal cord injury.

Authors:  Gong H Han; Wan-Kyu Ko; Seong J Kim; Daye Lee; Dabin Jeong; Inbo Han; Seung H Sheen; Seil Sohn
Journal:  Clin Transl Med       Date:  2022-07

2.  Neuroprotective Effects of Tauroursodeoxicholic Acid Involves Vascular and Glial Changes in Retinitis Pigmentosa Model.

Authors:  Laura Fernández-Sánchez; Henar Albertos-Arranz; Isabel Ortuño-Lizarán; Pedro Lax; Nicolás Cuenca
Journal:  Front Neuroanat       Date:  2022-04-12       Impact factor: 3.543

Review 3.  Neuroinflammation and Scarring After Spinal Cord Injury: Therapeutic Roles of MSCs on Inflammation and Glial Scar.

Authors:  Qi-Ming Pang; Si-Yu Chen; Qi-Jing Xu; Sheng-Ping Fu; Yi-Chun Yang; Wang-Hui Zou; Meng Zhang; Juan Liu; Wei-Hong Wan; Jia-Chen Peng; Tao Zhang
Journal:  Front Immunol       Date:  2021-12-02       Impact factor: 7.561

Review 4.  Hematogenous Macrophages: A New Therapeutic Target for Spinal Cord Injury.

Authors:  Yuanzhe Ding; Di Zhang; Sheng Wang; Xiaolei Zhang; Jingquan Yang
Journal:  Front Cell Dev Biol       Date:  2021-11-24

5.  Intratarget Microdosing for Deep Phenotyping of Multiple Drug Effects in the Live Brain.

Authors:  Jennifer Kim; Sebastian W Ahn; Kyle Deans; Devon Thompson; Benjamin Ferland; Prajan Divakar; Christine Dominas; Oliver Jonas
Journal:  Front Bioeng Biotechnol       Date:  2022-03-18

6.  Transplantation of neuron-inducing grafts embedding positively charged gold nanoparticles for the treatment of spinal cord injury.

Authors:  Wan-Kyu Ko; Seong Jun Kim; Gong Ho Han; Daye Lee; Dabin Jeong; Sang Jin Lee; In-Bo Han; Je Beom Hong; Seung Hun Sheen; Seil Sohn
Journal:  Bioeng Transl Med       Date:  2022-04-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.